Jefferies & Co disclosed Array Biopharma Inc (NASDAQ:ARRY), hiking its price target to $8.00 earlier today
- Updated: September 27, 2016
Jefferies & Co increased the price target of Array Biopharma Inc (NASDAQ:ARRY) to $8.00 indicating a possible upside of 0.26%.
On 9/26/2016, Leerink Swann released a statement for Array Biopharma Inc (NASDAQ:ARRY) bumped up the target price from $6.00 to $9.00 that suggested an upside of 0.36%.
Boasting a price of $6.33, Array Biopharma Inc (NASDAQ:ARRY) traded -3.48% lower on the day. With the last stock price close up 87.47% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Array Biopharma Inc has recorded a 50-day average of $3.61 and a two hundred day average of $3.40. Volume of trade was up over the average, with 38,067,868 shares of ARRY changing hands over the typical 3,506,770
With a total market value of $0, Array Biopharma Inc has with a one year low of $2.38 and a one year high of $7.27 .
A total of 7 equity analysts have released a ratings update on ARRY. Four equity analysts rating the company a strong buy, three equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $8.14.
Brief Synopsis About Array Biopharma Inc (NASDAQ:ARRY)
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.